Clinical Trial Update: A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. [Phase 3]

View source ↗

Summary

An ongoing Phase 3 trial is evaluating the safety and immunogenicity of a chikungunya virus-like particle vaccine in children, sponsored by Bavarian Nordic.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya

Drugs mentioned

• CHIKV VLP Vaccine (Chikungunya virus-like particle vaccine)

Snippet

Sponsor: Bavarian Nordic | Conditions: Chikungunya Virus | Phase 3 | Status: RECRUITING